Selinexor and Backbone Treatments of Multiple Myeloma Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Multiple Myeloma
Interventions
DRUG

Selinexor

Oral tablets

DRUG

Dexamethasone

Oral tablets

DRUG

Lenalidomide

Oral capsule

DRUG

Pomalidomide

Oral tablets

DRUG

Bortezomib

Subcutaneous Injection (single use vial)

DRUG

Daratumumab

Intravenous Infusion

DRUG

Carfilzomib

Intravenous infusion

DRUG

Ixazomib

Oral capsule

DRUG

Elotuzumab

Intravenous infusion

DRUG

Clarithromycin

Tablets

DRUG

Belantamab Mafodotin

Intravenous infusion

DRUG

Mezigdomide

Oral Capsules

Trial Locations (24)

10032

COMPLETED

Columbia University, New York

10065

COMPLETED

Weill Cornell Medicine, New York

27599

RECRUITING

University of North Carolina - Chapel Hill Comprehensive Cancer Center, Chapel Hill

27710

RECRUITING

Duke Institute of Cancer/ Duke University, Durham

37203

RECRUITING

Sarah Cannon- Tennessee Oncology Nashville, Nashville

53792

RECRUITING

University of Wisconsin School of Medicine and Public Health, Madison

68198

WITHDRAWN

University of Nebraska Medical Center, Omaha

80218

WITHDRAWN

Sarah Cannon-Colorado Blood Cancer Institute, Denver

85234

RECRUITING

Banner MD Anderson Cancer Center, Gilbert

98109

WITHDRAWN

Swedish Cancer Institute, Seattle

0095

RECRUITING

Jonnsson Comprehensive Cancer Center / University of Los Angeles, Los Angeles

02114

RECRUITING

Massachusetts General Hospital, Boston

02215

RECRUITING

Dana Farber Cancer Institute, Boston

07601

RECRUITING

Hackensack University Medical Center - John Theurer Cancer Center, Hackensack

Unknown

RECRUITING

Wilmot Cancer Center/ University of Rochester, Rochester

T2N 4Z6

WITHDRAWN

Tom Baker Cancer Center/Alberta Health Services, Calgary

T6G 1Z2

WITHDRAWN

Cross Cancer Institute / University of Alberta, Edmonton

V5Z 1M9

WITHDRAWN

Vancouver General Hospital, Vancouver

R3E 0V9

ACTIVE_NOT_RECRUITING

Cancer Care Manitoba, Winnipeg

A1B 3V6

COMPLETED

Memorial Hospital of Newfoundland, St. John's

B3H 2Y9

RECRUITING

Queen Elizabeth II Health Sciences Center, Halifax

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto

H1T 2M4

COMPLETED

Maisonneuve-Rosemont Hospital, Montreal

H3A 1A1

COMPLETED

Royal Victoria Hospital / McGill University, Montreal

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Karyopharm Therapeutics Inc

INDUSTRY